A risk model for ovarian carcinoma patients using CA 125: Time to normalization renders second-look laparotomy redundant

Cancer

Volumn 77, Issue 6, 1996, Pages 1122-1130

  Frasci, Giuseppe ^a,e   Conforti, Salvatore ^b   Zullo, Fulvio ^b   Mastrantonio, Pasquale ^b   Comella, Giuseppe ^d   Comella, Pasquale ^d   Persico, Giovanni ^a   Iaffaioli, Rosario Vincenzo ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY MEDITERRANEA OF REGGIO CALABRIA   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e NONE   (Italy)

Author keywords

CA 125; multivariate analysis; ovarian carcinoma; risk model; second look laparotomy

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; TISSUE POLYPEPTIDE ANTIGEN;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; SECOND LOOK SURGERY; SURVIVAL TIME; TUMOR VOLUME;

CA-125 ANTIGEN; FEMALE; HUMANS; LAPAROTOMY; MODELS, STATISTICAL; OVARIAN NEOPLASMS; PROGNOSIS; REOPERATION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0029876540     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1122::AID-CNCR18>3.0.CO;2-3     Document Type: Article

References (32)

1. Brenner DE, Shaff MI, Jones HV, Grosh WW, Greco FA, Burnett LS. Abdominopelvic computed tomography: Evaluation in patients undergoing second-look laparotomy for ovarian carcinoma. Obstet Gynecol 1985;65:715-9.
2. Rubin SC, Hoskins WJ, Hakes TB, Markman M, Cain JM, Lewis JL Jr. Recurrence following negative second-look laparotomy for ovarian cancer: Analysis of risk factors. Am J Obstet Gynecol 1988; 159:1094-8.
3. Hoskins WJ. The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer. Baillieres Clin Obstet and Gynaecol 1989; 3:59-71.
4. Sorbe B, Frankendal BO, Veress B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 1982;59:576-82.
5. Swenerton KD, Hislop TG, Spinelli J, Leriche JC, Yang N, Boyes DA. Ovarian carcinoma: A multivariate analysis of prognostic factors. Obstet Gynecol 1985;65:264-9.
6. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Symposium on ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:101-4.
7. Redman JR, Petroni GR, Saigo PE, Geller NL, Hakes TB. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol 1986; 4:515-23.
8. Lippman SM, Alberts DS, Slymen DJ, Weiner S, Aristizabal SA, Luditch A, et al. Second-look laparotomy in epithelial ovarian cancer. Prognostic factors associated with survival duration. Cancer 1988;61:2571-7.
9. Friedlander ML, Hedley DW, Swanson C, Russel P. Prediction of long term survivals by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. J Clin Oncol 1988;6:282-90.
10. Creasman WT, Gall S, Bundy BN, Beecham J, Mortel R, Homesley HD. Second-look laparotomy in the patient with minimal residual stage III ovarian cancer. A Gynecologic Oncology Group Study. Gynecol Oncol 1989;35:378-82.
11. Van Houwelingen JC, ten Bokkel Huinink WW, van der Burg MEL, van Oosterom AT, and Neijt JP. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol 1989;7:769-73.
12. Niloff JM, Bast RC Jr., Schaetzl EM, Knapp RC. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 1985;151:981-6.
13. Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM. CA 125 levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 1986;67:685-9.
14. Rubin SC, Hoskins WJ, Hakes TB, Markman M, Reichman BS, Chapman D, et al. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol 1989;3:667-71.
15. Rustin GJ, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshawe KD. Use of CA 125 to predict survival of patients with ovarian carcinoma. J Clin Oncol 1989;7:1667-71.
16. Frasci G, Contino A, Iaffaioli RV, Mastrantonio P, Conforti S, Persico G. Computerized tomography of the abdomen and pelvis with peritoneal administration of soluble contrast (IPC-CT) in detection of residual disease for patients with ovarian cancer. Gynecol Oncol 1994;52:154-60.
17. Kaplari ES, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assac 1958;53:557-80.
18. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
19. Wilkinson L. Systat: The system for statistics. Evanston: Systat Inc., 1988.
20. Lund B, Williamson P, van Houwelingen HC, Neijt JP. Comparison of the predictive power of different prognostic indices for overall survival in patients with advanced ovarian carcinoma. Cancer Res 1990;50:4626-9.
21. Moore JL Jr, Barter JF. Second-took laparotomy. Semin Surg Oncol 1994;10:276-82.
22. Copeland LJ, Vaccarello L, Lewandowski GS. Second-look laparotomy in epithelial ovarian cancer. Obstet Gynecol Clin North Am 1994;21:155-66.
23. Zorlu CG, Cobanoglu O, Caglar T, Ergun Y, Kuscu E, Alaybeyoglu T. How does negative clinical evaluation of ovarian carcinoma after full course of chemotherapy correlate with second-look laparotomy findings? J Surg Oncol 1994;55:255-8.
24. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992;44:207-12.
25. Redman CWE, Blackledge GR, Krystyna K, Powel J, Buxton EJ, Luesley DM. Early serum CA 125 response and outcome in epithelial ovarian cancer. Eur J Cancer 1990:26:593-6.
26. Ron IG, Inbar M, Gelernter I, Lewysohn O, Ayalon D, Dale J, et al. Use of CA 125 response to predict survival parameters of patients with advanced ovarian carcinoma. Acta Obstet Gynecol Scand 1994;73:658-62.
27. Van der Burg MEL, Lammes FB, Van Putten WLJ, Stoter G. Ovarian cancer: the prognostic value of the serum half life of CA 125 during induction chemotherapy. Gynecol Oncol 1988;30:307-12.
28. Liu PY, Alberts DS, Federico M, Hannigan EV, Garcia DJ, Rothenberg ML, et al. CA 125 concentration 8 weeks after treatment initiation independently predicts survival in patients with advanced epithelial ovarian cancer: A Southwest Oncology Group (SWOG) study. In: Perry MC, editors. Proceedings of the American Society of Clinical Oncology; 1995 May 20-23; Los Angeles (CA). American Society of Clinical Oncology, 1995.
29. Creasman WT, Eddy GL. Prognostic factors in relation to second-look laparotomy in ovarian cancer. Baillieres Clin Obstet Gynaecol 1989;3:183-90.
30. Frasci G, Tortoriello A, Facchini G, Conforti S, Cardone A, Persico G, et al. Intraperitoneal (I.P.) Cisplatin-mitoxantrone-alpha 2b interferon in ovarian cancer patients with minimal residual disease. Gynecol Oncol 1993;50: 60-7.
31. Howell S, Zimm S, Markman M, Abramson IS, Cleary S, Lucas WE, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987;10:1607-12.
32. Markman M, Reichman B, Hakes T, Jones W, Lewis JC, Rubin S, et al. Responses to second-line cisplatin-based intraperitoneal chemotherapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9:1801-5.